These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 19581539)

  • 21. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
    Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).
    Ghielmini M; Schmitz SF; Cogliatti S; Bertoni F; Waltzer U; Fey MF; Betticher DC; Schefer H; Pichert G; Stahel R; Ketterer N; Bargetzi M; Cerny T;
    J Clin Oncol; 2005 Feb; 23(4):705-11. PubMed ID: 15598978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy.
    Prescrire Int; 2010 Dec; 19(111):276-8. PubMed ID: 21355378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
    Girinsky T; Lapusan S; Ribrag V; Koscielny S; Ferme C; Carde P
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):476-9. PubMed ID: 15667970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    O'Connor OA; Portlock C; Moskowitz C; Straus D; Hamlin P; Stubblefield M; Dumetrescu O; Colevas AD; Grant B; Zelenetz A
    Br J Haematol; 2008 Oct; 143(2):201-9. PubMed ID: 18691173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
    Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
    J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    Atkins MB; Hidalgo M; Stadler WM; Logan TF; Dutcher JP; Hudes GR; Park Y; Liou SH; Marshall B; Boni JP; Dukart G; Sherman ML
    J Clin Oncol; 2004 Mar; 22(5):909-18. PubMed ID: 14990647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
    Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
    Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
    Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
    Coiffier B; Ribrag V
    Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
    Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
    Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
    J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.